SubstanceAdminSubstitution

Substance Admin Substitution

activeExtensions for Using Data Elements from FHIR R5 in FHIR R40.1.0complete10 concepts

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

Metadata

hl7.org/fhir
Canonical URL
http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution
ID
v3-substanceAdminSubstitution
Version
2.1.0
Publisher
FHIR Infrastructure
Case Sensitive
Yes
Hierarchy
is-a

Concepts (10)

CodeDisplayDefinition
_ActSubstanceAdminSubstitutionCodeActSubstanceAdminSubstitutionCode**Description:** Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
└Eequivalent**Description:** Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
└ECequivalent composition**Description:** Substitution occurred or is permitted with another product that is a: * pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester * pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration *Examples:* * *Pharmaceutical alternative:* Erythromycin Ethylsuccinate for Erythromycin Stearate * *Pharmaceutical equivalent:* Lisonpril for Zestril
└BCbrand composition**Description:** Substitution occurred or is permitted between equivalent Brands but not Generics *Examples:* * Zestril for Prinivil * Coumadin for Jantoven
└Ggeneric composition**Description:** Substitution occurred or is permitted between equivalent Generics but not Brands *Examples:* * Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
└TEtherapeutic alternative**Description:** Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. *Examples:* * ranitidine for Tagamet
└TBtherapeutic brand**Description:** Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > *Examples:* * Zantac for Tagamet
└TGtherapeutic generic**Description:** Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > *Examples:* * Ranitidine for cimetidine
└Fformulary**Description:** This substitution was performed or is permitted based on formulary guidelines.
└NnoneNo substitution occurred or is permitted.